Blood Task Force

Mission Statement

The Extracellular Vesicle (EV) Blood Task Force is dedicated to advancing reproducibility, standardization, and scientific rigor specifically in blood-derived EV research. Through collaborative efforts, the development of standardized methodologies, evidence-based guidelines, and rigorous quality control measures, we aim to facilitate meaningful clinical translation and foundational biological understanding in blood EV studies.

Vision Statement

To establish and maintain globally recognized standards and best practices for extracellular vesicle research. Our vision is a future in which all EV research employs harmonized methods, transparent reporting, and robust quality assurance practices, enabling significant advances in biomarker discovery, therapeutic applications, and basic biological insights.

Working Groups

Working Group #1: Collection, handling and storage of blood extracellular vesicles 

Working Group #2: Quality controls of plasma and serum 

Working Group #3: Quality controls for EV preparations from plasma and serum 

Working Group #4: Clinical applications of blood EV research

Working Group #5: Education & Outreach 

Chair Contact Info

Fabrice Lucien-Matteoni and Dakota Gustafson

Members 

 

Working Group 1 Working Group 2 Working Group 3 Working Group 4 Working Group 5
Daniel Hagey (Co-Lead) Christina Coughlan (Lead) David Greening (Co-Lead) Andrew Rowland (Co-Lead) Rienk Nieuwland (Co-Lead)
Karla Williams (Co-Lead) Lucio Barile Shinicho Kano (Co-Lead) Andre J van Wijnen (Co-Lead) Dolores Di Vizio (Co-Lead)
Eunju Seong Eisuke Dohi Ryan Pink Jillian Bracht Prashant Kumar
Tomas Dias Eric Boilard Andre Gorgens Zani Augusto Natalie Turner
Petra Rohrbach Britta Bettin Prasenjit Mitra

Faisal Alibhai

 

Faezeh Shekari

Pia Siljander

Rebecca Simmons

Amanda Salviano da Silva 

Joaquin Seras

Elizabeth Dellar

Kimberly Luke  

 

Publications

Other Outputs

  • Several Blood EV TF members involved in organizing the Helsinki Blood EV Workshop (Helsinki, Finland; 2022), ISTH endorsed (showing the interest of a more clinical scientific society on this topic) 
  • Initially, we identified several caveats, including the lack of a roadmap to gain a comprehensive overview of expected challenges (2019), the lack of robust quality controls to improve blood-derived starting material for EV isolation and characterization (hope to publish this early 2023), and now we have a few of the originally identified topics left (i) Anticoagulants, (ii) Blood stabilization tubes, and (iii) Reference plasma samples. Propose to have a discussion at ISEV 2023 amongst the Blood EV TF members which topics we should focus on next.
View All Task Forces